 WALTHAM, Mass., April 15, 2021 PRNewswire -- Syndax Pharmaceuticals, Inc. Syndax, the Company or we Nasdaq:SNDX, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 12 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021 at 8:00 a.m. 